drugset / Trial / NCT04037397

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

NCT04037397 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if catheter-based atrial fibrillation (AF) ablation is superior to treatment with antiarrhythmic drugs as a first-line therapy for symptomatic persistent AF.

Timeline

Start
2019-09-24
Primary completion
2024-10-01
Completion
2024-10-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amiodarone Small molecule — —
Comparator Dofetilide Small molecule — —
Comparator Dronedarone Small molecule — —
Comparator Flecanide Unknown — —
Comparator propafenone Unknown — —
Comparator sotalol Small molecule — —

Indications